Ganga Pharmaceuticals has notified the stock exchange of a scheduled Board of Directors meeting on May 21, 2026, in compliance with Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The meeting has been called to consider and approve the audited financial results of the company for the half year and financial year ended March 31, 2026.

Board Meeting Details

The intimation, dated May 14, 2026, was submitted to BSE Limited and outlines the key agenda and trading window provisions associated with the upcoming board meeting. The key details of the scheduled meeting are as follows:

Trading Window Closure

Pursuant to the company's Code of Conduct for Prevention of Insider Trading, the Trading Window for dealing in Ganga Pharmaceuticals' securities has been closed from April 01, 2026, for all Designated Persons of the company. The Trading Window will reopen 48 hours after the audited financial results are declared to the stock exchange.

The intimation was signed by Bharat Sharma, Managing Director of Ganga Pharmaceuticals (DIN: 00077026), on May 14, 2026.

Ganga Pharmaceuticals Limited has announced the implementation of a special window facility to assist shareholders with the transfer and dematerialisation of physical securities. The initiative represents a significant opportunity for shareholders holding physical share certificates to convert them to electronic format under regulatory guidelines.

SEBI Circular Implementation

The special window has been established pursuant to SEBI Circular No. HO/3813/11/2/2026-MIRSD-POD/I/3750/2026 dated January 30, 2026. The facility will remain operational for a period of one year, commencing from February 05, 2026 and concluding on February 04, 2027.

Eligible Cases

The special window facility will be applicable in specific scenarios related to physical securities transactions. The company has outlined two primary categories of eligible cases for shareholders to utilize this facility.

Eligible shareholders include those where original share transfer requests were not lodged prior to April 01, 2019, and the shareholder continues to hold the original share certificate. Additionally, the facility covers cases where original share transfer requests were lodged prior to April 01, 2019, but were subsequently rejected, returned, or not attended due to deficiencies in documents, processes, or other issues, with the shareholder still holding the original share certificate.

Processing Requirements

Shareholders seeking to utilize this facility must furnish necessary documents to the company's designated Registrar and Share Transfer Agent. KFin Technologies Limited has been appointed to handle the processing of these requests.

Transfer Conditions

The company has specified important conditions that will apply to shares processed through this special window. All shares will be mandatorily credited to the transferee only in demat mode, ensuring electronic holding of the securities.

A significant restriction applies to the transferred shares, which will be subject to a lock-in period of one year from the date of registration of transfer. During this lock-in period, the securities cannot be transferred, lien marked, or pledged, providing regulatory protection for the transfer process.

Company Communication

The announcement was made through newspaper publications in "Financial Express" (English) and "Mumbai Lakshdeep" (Marathi) on March 14, 2026. The information has also been made available on the company's website at www.ayurvedganga.com for shareholder reference and accessibility.